Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
36 filings of GLENMARK since November 2024.
presentation 10, board outcome 9, transcript 8, dividend 3, credit rating 3, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 09 Nov 2026 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed the transcript of its earnings call held on November 06, 2026 for the quarter and half year ended September 30, 2026. The filing is a cover letter stating that the transcript has been uploaded to the company's website; the transcript text itself is not included in the pages provided. No financial figures, guidance or management commentary are included in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | presentation Guidance, Results | Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investors Presentation'.AI summaryGlenmark Pharmaceuticals filed its Q2 FY27 investor presentation (dated 05 November 2026) under Regulation 30 of the SEBI Listing Obligations rules. Q2 FY27 consolidated revenue was Rs 42,473 million, down 29.8% YoY from Rs 60,469 million but up 5.7% QoQ; like-for-like YoY growth was about 20%. Q2 FY27 EBITDA was Rs 8,638 million (20.3% margin); adjusted PAT was Rs 4,852 million (11.4% margin); consolidated R&D was Rs 3,449 million. India business grew about 14% like-for-like YoY; North America core business grew about 31% (excluding deferred out-licensing income for ISB 2001); Europe grew 6.2% and Emerging Markets 33.2%. Chairman and MD Glenn Saldanha said management remains on track to deliver FY27 guidance and expects the first partnered oncology launch by the end of FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | board outcome Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryGlenmark Pharmaceuticals filed the outcome of its board meeting held on November 05, 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the limited review report. Consolidated total revenue from operations for the quarter ended September 30, 2026 was INR 42,473.28 million, against INR 40,184.83 million for the quarter ended June 30, 2026 (amounts as printed, in million rupees). Consolidated profit after tax attributable to owners of the parent for the quarter ended September 30, 2026 was INR 2,637.83 million, against INR 4,829.24 million for the quarter ended June 30, 2026. Consolidated basic EPS for the quarter ended September 30, 2026 was INR 9.35, against INR 17.11 for the quarter ended June 30, 2026. The meeting commenced at 1:15 p.m. and concluded at 4:15 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Sep 2026 | credit rating Guidance, Rating, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryGlenmark Pharmaceuticals filed under Regulation 30 a rating rationale from India Ratings and Research dated September 10, 2026. India Ratings upgraded GPL's long-term bank loans to 'IND AA+'/Stable from 'IND AA' and affirmed short-term bank loans at 'IND A1+'. Rated bank loan facilities of INR18,500 million (long-term rating upgraded, short-term affirmed) and INR23,500 million (newly assigned 'IND AA+/Stable/IND A1+'). The rationale cites the ISB 2001 licensing deal with AbbVie, under which GPL recognised USD560 million in FY26 of the USD700 million upfront payment, with USD70 million each due in FY27 and FY28. Management expects FY27 revenue of INR170-180 billion and an EBITDA margin of 21%-22%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed the transcript of its earnings call held on August 3, 2026 for the quarter ended June 30, 2026. The transcript has been uploaded to the company's website, with the link given in the letter. The filing itself, which is a cover letter, does not state any financial figures or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2026 | presentation Results | Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investor Presentation'.AI summaryGlenmark Pharmaceuticals filed its Investor Presentation for Q1 FY27 (quarter ended June 30, 2026), dated July 31, 2026. Consolidated revenue was Rs. 40,185 million, up 23.1% YoY from Rs. 32,644 million; North America revenue was Rs. 10,974 million (up 41.1%, including deferred out-licensing income for ISB 2001), and India revenue was Rs. 14,321 million (up 15.5%). Consolidated EBITDA was Rs. 8,048 million (EBITDA margin 20.03%); PAT was Rs. 4,828 million (PAT margin 11.8%); consolidated R&D was Rs. 2,494 million. Chairman and Managing Director Glenn Saldanha said the company started FY27 with broad-based growth, with RYALTRIS continuing to grow globally and WINLEVI gaining traction across Europe. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2026 | board outcome Dividend / buy-back, Management change, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Glenmark Pharmaceuticals approved unaudited standalone and consolidated results for the quarter ended June 30, 2026, and the related limited review report. Standalone net sales for the quarter were Rs 23,425.26 million and standalone profit after tax was Rs 7,356.37 million; consolidated net sales were Rs 39,317.30 million and consolidated profit after tax was Rs 4,828.28 million, with consolidated basic EPS of Rs 17.11. Standalone exceptional items were a gain of Rs 2,230.00 million for the quarter; consolidated exceptional items were Rs 3,733.99 million (loss) for the quarter per the printed table. The 48th AGM is set for September 11, 2026, and the record date for the FY2025-26 dividend entitlement is August 31, 2026; the dividend amount is not stated in the pages provided. The Board also amended five policies and reconstituted the Risk Management Committee effective August 1, 2026, with Ms. Patricia Andrews as Chairperson. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Jun 2026 | presentation Guidance | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed the presentation for its Investor Day 2026, held on June 9, 2026 in Mumbai. Management stated the company has about US$2bn consolidated revenue (FY26, converted at ₹88.33 per US$), about 17,000 employees, 11 manufacturing sites, and operations in more than 80 countries. Management said more than 60% of revenue is expected to come from the branded portfolio, based on FY27e consolidated revenue. Management described its three focus areas as oncology, dermatology and respiratory, and cited more than 9 active partnerships for innovative products. The presentation covers the agenda of speakers on global growth, shareholder value, next-gen biologics and therapy areas. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | presentation Acquisition, Legal, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q4 FY26 investor presentation (dated 29 May 2026) under Regulation 30 of the SEBI LODR Regulations. Q4 FY26 consolidated revenue was Rs. 37,706 million, up 15.8% YoY; EBITDA was Rs. 7,626 million (margin 20.2%); PAT was Rs. 3,013 million (PAT margin 7.6%). Full-year FY26 consolidated revenue was Rs. 169,825 million, up 27.5% YoY; North America revenue rose to Rs. 71,390 million, including deferred out-licensing income recognition for ISB 2001. Regional Q4 YoY growth: India 8.2%, North America core business 7.8%, Europe 21.4%, Emerging Markets 13.7%. Chairman and Managing Director Glenn Saldanha said FY26 was a defining year, citing the AbbVie partnership for ISB 2001 (USD 700 million upfront, potential total deal value USD 1.925 billion) and the US launches of generic respiratory products. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Management change | The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and Appointment of Senior Management PersonneAI summaryGlenmark Pharmaceuticals' board, at its meeting held May 29, 2026, noted the early retirement of Mr. Harish Kuber as Company Secretary & Compliance Officer, effective close of business hours of May 29, 2026. The board approved the appointment of Ms. Rashmi Khandelwal (ACS 28839) as Company Secretary & Compliance Officer (KMP), effective May 30, 2026, on the recommendation of the Nomination and Remuneration Committee. Mr. Samir Kazi, Executive Vice President & Head Legal, Compliance & IP, has been appointed as Senior Management Personnel. The board meeting commenced at 4:30 p.m. and ended at 7:26 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | dividend Dividend / buy-back, Results | Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share.AI summaryGlenmark Pharmaceuticals' board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. Standalone net loss for FY2025-26 was Rs 2,007.99 million, against a profit of Rs 16,103.50 million in FY2024-25; total revenue from operations for the year was Rs 84,400.99 million. Consolidated profit for the year attributable to owners was Rs 13,618.51 million (basic EPS Rs 48.26), against Rs 10,470.97 million in the prior year; consolidated revenue from operations was Rs 1,69,825.11 million. The board recommended a final dividend of Rs 2.5 per share (face value Re 1) for FY2025-26, subject to shareholder approval at the ensuing AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Dividend / buy-back, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryGlenmark Pharmaceuticals' board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. Consolidated FY2026 total income was Rs 174,431.30 million and profit after tax attributable to owners was Rs 13,618.51 million, against Rs 10,470.97 million in FY2025; Q4 FY2026 consolidated profit after tax attributable to owners was Rs 3,014.14 million. Standalone FY2026 result was a loss after tax of Rs 2,007.99 million, against a profit of Rs 16,103.50 million in FY2025, after exceptional items of Rs 18,008.58 million. The board recommended a final dividend of Rs 2.5 per share (250% on face value of Re 1), subject to shareholder approval at the ensuing AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Feb 2026 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed the transcript of its earnings call held on February 2, 2026 for the third quarter and nine months ended December 31, 2025. The company said the transcript has been uploaded to its website; the filing itself does not include the call content. The filing is a routine submission under Regulation 30(6) of SEBI (LODR) Regulations, 2015. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | presentation Guidance, Legal, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q3 FY26 investor presentation dated 30 January 2026 under Regulation 30 of the SEBI LODR Regulations. Q3 FY26 consolidated revenue was Rs. 39,006 Mn, up 15.1% YoY; EBITDA was Rs. 8,697 Mn (22.3% margin); PAT was Rs. 4,032 Mn (10.3% margin), including an exceptional item of Rs. 1,843 Mn mainly due to India's New Labour Codes. Regional growth in Q3 FY26: India 22.1%, North America 24.2% (core business 4.1% excluding ISB 2001 out-licensing income), Europe 9.1%, Emerging Markets 8.4%. Management (Chairman and MD Glenn Saldanha) said the company is on track to deliver its near-term guidance and that WINLEVI® has received EU approval, with launch planned by Q1 FY27. The US FDA issued a VAI classification for the Monroe manufacturing site, and four injectable products were launched in North America. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | board outcome Legal, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine Monthsended 31st December, 2025.AI summaryGlenmark Pharmaceuticals' board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 at a meeting held on 30 January 2026 (meeting 4:30 pm to 6:40 pm). Consolidated net sales for Q3 FY26 (quarter ended 31/12/2025) were Rs 38,879.99 million, against Rs 60,037.94 million in Q2 (quarter ended 30/09/2025) and Rs 33,019.04 million in Q3 FY25. Consolidated profit after tax for Q3 FY26 was Rs 4,032.28 million, against Rs 6,104.32 million in the previous quarter and Rs 3,480.31 million in the year-ago quarter; consolidated basic EPS was Rs 14.29. Standalone profit before tax for Q3 FY26 was Rs 2,820.66 million on revenue from operations of Rs 23,599.35 million. Note 5 records a provision of Rs 3,232.32 million (US$ 37.75 million) for a proposed settlement with the putative direct purchaser class in US generic drug antitrust lawsuits, subject to court approval; the company denies the allegations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Nov 2025 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed the transcript of its Q2 and H1 FY26 earnings call, held on November 17, 2025, for the quarter and half year ended September 30, 2025. The transcript has been uploaded to the company's website; the filing itself does not contain the call content. The filing is a covering letter under Regulation 30(6) of SEBI (LODR) Regulations, 2015, referring to an earlier letter dated November 6, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | presentation Acquisition, Guidance, Legal, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q2 FY26 investor presentation (dated November 14, 2025) under Regulation 30. Consolidated revenue for Q2 FY26 was Rs 60,469 Mn, up 76.1% YoY, with EBITDA of Rs 23,596 Mn (39.0% margin) and PAT of Rs 6,104 Mn (10.1% margin). The presentation covers the AbbVie partnership for ISB 2001 with a US$700 million upfront payment, of which Q2 revenue recognition is US$525 million. India revenue fell to Rs 1,650 Mn from Rs 12,817 Mn YoY, which management attributed to the GST regime change, a one-time reduction in distributor inventory and order postponements. Management estimates ROCE of 25-30% and ROE of 20-25% in FY27, and reported one-time provisions and charges for FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | board outcome Management change, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, Unaudited Financial Results (Standalone and Consolidated) for the Second Quarter and Half Yearended 30th September, 2025.AI summaryGlenmark Pharmaceuticals approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 at a board meeting held on 14 November 2025. Standalone Q2 FY26 (quarter ended 30/09/2025): total revenue from operations Rs 15,386.60 million; loss after tax Rs (7,391.89) million, after exceptional items of Rs 9,317.94 million; basic EPS Rs (26.19). Consolidated Q2 FY26: total revenue from operations Rs 60,468.70 million; profit after tax Rs 6,104.32 million; exceptional items of Rs 13,851.16 million; basic EPS Rs 21.63. Consolidated half year ended 30/09/2025: total revenue from operations Rs 93,113.10 million; profit after tax Rs 6,574.05 million. The board also reconstituted the ESG Committee effective 1 December 2025, with Mr. Pradeep Kumar Sinha as Chairman and Mr. Glenn Saldanha, Ms. Sona Saira-Ramasastry and Ms. Patricia Andrews as Members. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Sep 2025 | dividend Dividend / buy-back, Management change | Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on September 26, 2025, declared Interim Dividend of 2.5 per equity share.AI summaryGlenmark Pharmaceuticals' board on 26 September 2025 approved an interim dividend of ₹2.50 per equity share (face value ₹1) for FY 2025-26, amounting to ₹705.50 million. The record date for the interim dividend is Friday, 3 October 2025, as intimated earlier on 22 September 2025; the dividend will be paid within 30 days of declaration. The board reconstituted its Stakeholders Relationship, Risk Management and ESG committees with effect from 1 October 2025. The board meeting commenced at 10:00 a.m. IST and concluded at 10:21 a.m. IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Sep 2025 | credit rating Acquisition, Guidance, Rating | Glenmark Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryCRISIL Ratings revised the outlook on Glenmark Pharmaceuticals' long-term bank facilities to 'Positive' from 'Stable' and reaffirmed the long-term rating at 'Crisil AA'; short-term rating reaffirmed at 'Crisil A1+' (rating rationale dated September 18, 2025). Total bank loan facilities rated: Rs.1850 crore. The outlook revision follows the exclusive global licensing deal with AbbVie Inc. for ISB 2001, under which Glenmark received an upfront payment of USD 700 million on September 9, 2025, with milestone payments of up to USD 1.225 billion and double-digit royalties. CRISIL states that the upfront payment is expected to significantly improve the company's financial risk profile, and cites FY25 revenue of Rs.13,321 crore (up 13% on-year on a like-to-like basis). Upward factors include double-digit revenue growth with operating profit sustained above 20%; downward factors include divergence in deployment of deal proceeds and sluggish performance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Aug 2025 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed a letter to NSE and BSE on August 28, 2025, giving the transcript of its Q1 FY26 earnings call (quarter ended June 30, 2025). The earnings call was held on Monday, August 18, 2025. The transcript has been uploaded on the company's website; the letter does not state its contents. The filing is signed by Harish Kuber, Company Secretary & Compliance Officer. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2025 | presentation Guidance, Legal, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q1 FY26 investor presentation dated August 14, 2025. Consolidated revenue was Rs. 32,644 Mn, up 0.6% YoY; US (North America) business grew 8.9% QoQ and India business grew 3.7% YoY. EBITDA was Rs. 5,805 Mn with a 17.8% margin; Adjusted PAT was Rs. 3,129 Mn (9.6% margin), adjusted for an exceptional item related to the US litigation settlement (reported PAT was Rs. 470 Mn). Chairman and Managing Director Glenn Saldanha said the company remains confident in its strategy and expects Europe to deliver double-digit growth from the second quarter onwards. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2025 | board outcome Acquisition, Capex, Legal, Management change | Glenmark Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 14, 2025.AI summaryGlenmark Pharmaceuticals filed the outcome of its board meeting held on August 14, 2025. The board approved transfer of the Consumer Care business to its newly incorporated wholly owned subsidiary Glenmark Consumer Care Limited; the business had FY2025 turnover of INR 514.7 Crs (5.6% of standalone turnover) and the transfer is expected at about INR 240.40 Crores, with completion expected on or before December 31, 2025. The board appointed Ms. Patricia Andrews (DIN 11211749) as Additional Director (Non-Executive, Independent) for a term from August 14, 2025 to August 13, 2030, subject to shareholder approval. The board recommended M/s. Walker Chandiok & Co., LLP as Statutory Auditors and M/s. Rauthan & Associates LLP as Secretarial Auditors, each for five years, subject to shareholder approval. The 47th Annual General Meeting is scheduled for September 26, 2025 at 2:00 P.M. IST through video conferencing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2025 | board outcome Legal, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryGlenmark Pharmaceuticals filed its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025, approved by the Board on 14 August 2025 (meeting 2:00 p.m. to 4:11 p.m.). Standalone Q1 FY26 total income was Rs 24,642.63 million and profit after tax was Rs 3,296.92 million, against Rs 4,529.16 million in the quarter ended 30 June 2024. Consolidated Q1 FY26 total income was Rs 32,908.82 million and profit after tax was Rs 469.73 million, with profit attributable to owners of the company of Rs 468.71 million. Both figures include an exceptional charge of Rs 3,232.32 million (US$ 37.75 million) provided for a proposed settlement with a putative direct purchaser class in US antitrust and consumer protection lawsuits over generic drugs; the settlement is subject to court approval and Glenmark denies the allegations. Basic EPS on a consolidated basis was Rs 1.66 for the quarter, not annualised. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | credit rating Acquisition, Rating, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating- RevisionAI summaryGlenmark Pharmaceuticals filed an India Ratings and Research rating rationale dated July 23, 2025 under Regulation 30 of the SEBI LODR Regulations. India Ratings revised the Outlook on Glenmark's long-term bank facilities to Positive from Stable and affirmed the rating at 'IND AA'; short-term non-fund-based limits were affirmed at 'IND A1+'. Rated facilities cover fund-based working capital limits of INR4,500 million and proposed fund-based limits of INR7,500 million (both IND AA/Positive), and non-fund-based limits of INR4,400 million and proposed non-fund-based limits of INR2,100 million (both IND A1+). The rationale cites the AbbVie out-licensing deal for ISB 2001, with an upfront payment of USD700 million and milestones of up to USD1.225 billion, and FY25 consolidated revenue growth of 12.8% to INR133.2 billion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Jul 2025 | presentation Guidance | Glenmark Pharmaceuticals Limited has informed the Exchange about PresentationAI summaryGlenmark Pharmaceuticals filed the investor presentation for its Investor Day 2025, held in Mumbai on July 16, 2025. The presentation describes the company as having about US$1.6 billion consolidated revenue (FY25), 11 manufacturing sites, 15,000+ employees, presence in over 80 countries, and more than 60% of revenue from branded markets. It states that more than 15 molecules have progressed through clinical development and that 10 out-licensing deals have been executed since 2004. Management outlines a 2025-2030 plan to grow the innovative and branded business, expand in high-growth EU and EM markets, grow the US generic business, and build an innovation pipeline in multispecifics, with the aim of becoming a leading global innovation-driven company. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2025 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed the transcript of its Q4 and FY2025 (year ended March 31, 2025) earnings call, held on May 26, 2025. The transcript has been uploaded to the company's website; the filing itself contains no financial figures. The filing is a cover letter under Regulation 30(6) of SEBI LODR, referencing an earlier letter dated May 19, 2025. Management's remarks are not reproduced in the pages provided, so no tone can be assessed from this filing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 May 2025 | presentation Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q4 FY25 investor presentation dated May 23, 2025. Q4 FY25 consolidated revenue was Rs. 32,562 Mn, up 6.3% YoY; Europe business grew 19.9% YoY in the quarter. Q4 FY25 EBITDA was Rs. 5,607 Mn (17.2% margin); adjusted PAT was Rs. 3,466 Mn (10.6% margin), adjusted for one-time exceptional items and legal costs related to generic Zetia litigation and closure of the La Chaux-de-Fonds facility. FY25 consolidated revenue was Rs. 133,217 Mn, up 12.8% YoY; R&D expenditure in Q4 FY25 was Rs. 2,367 Mn (7.3% of revenue). Chairman and Managing Director Glenn Saldanha said the performance reflected the resilience of the business and the strength of its diversified portfolio, and that the company remains committed to building momentum as it strengthens its global footprint in FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 May 2025 | dividend Dividend / buy-back, Results | Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2025, recommended Final Dividend of Rs. 2.5 per equity share.AI summaryGlenmark Pharmaceuticals' board, at its meeting on 23 May 2025, approved audited financial results for the quarter and year ended 31 March 2025, filed with the auditors' report and an unmodified opinion declaration. The board recommended a final dividend of 250% (Rs. 2.5 per share on face value Re. 1 each) for FY 2024-25, subject to shareholder approval at the ensuing AGM. The filing's figures are in millions of Indian Rupees; the standalone and consolidated results and balance sheet are attached. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 May 2025 | board outcome Dividend / buy-back, Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryGlenmark Pharmaceuticals' board, at its meeting on 23 May 2025, approved the audited financial results for the quarter and year ended 31 March 2025, with auditors' report and unmodified opinion declaration. The board recommended a final dividend of 250% (Rs. 2.5 per share, face value Re. 1 each) for FY 2024-25, subject to shareholder approval at the ensuing AGM. Standalone statements show quarterly total revenue from operations of Rs. 20,094.93 million in the quarter ended 31 March 2025 (figures as printed in the filing; the standalone quarterly figure is not clearly legible in the scanned text, so it is not stated here). Consolidated annual total revenue from operations for FY 2024-25 is printed as Rs. 1,31,458.36 million, with consolidated profit after tax attributable to owners of the company of Rs. 10,470.97 million (as read from the scanned text). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Feb 2025 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed a letter dated February 19, 2025 with the stock exchanges (NSE and BSE) attaching the transcript link for its earnings call. The earnings call was held on Monday, February 17, 2025, covering the third quarter ended December 31, 2024. The transcript has been uploaded to the company's website; the filing itself does not contain the call's content or management's comments. The letter is signed by Harish Kuber, Company Secretary & Compliance Officer. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Feb 2025 | results Results | Integrated Filing (financials) for the Third Quarter and Nine Months ended December 31,2024AI summaryGlenmark Pharmaceuticals filed its integrated financial results for the quarter and nine months ended December 31, 2024, under SEBI circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185, and the board approved them on February 14, 2025. Consolidated net sales for the quarter ended December 31, 2024 were INR 33,019.04 million, against INR 34,004.98 million in the previous quarter (September 30, 2024) and INR 24,602.90 million in the year-ago quarter. Consolidated profit after tax from continuing operations attributable to owners of the company for the quarter ended December 31, 2024 was INR 3,479.62 million (basic EPS INR 12.33 on the quarter's continuing operations line as printed in the statement). Consolidated total income for the quarter ended December 31, 2024 was INR 34,186.80 million; standalone revenue from operations was INR 13,650.96 million. The results were reviewed by the audit committee on February 13, 2025, and the statutory auditors issued an unmodified limited review report. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Feb 2025 | presentation Guidance, Results | Glenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryGlenmark Pharmaceuticals filed its Q3 FY25 investor presentation dated February 14, 2025 under Regulation 30 of the SEBI LODR Regulations. Consolidated revenue for Q3 FY25 was Rs. 33,876 Mn, up 35.1% YoY; EBITDA was Rs. 6,002 Mn (17.7% margin); PAT was Rs. 3,480 Mn (10.3% margin). India business revenue was Rs. 10,637 Mn; Europe grew 14.8% YoY; R&D expenditure was Rs. 2,249 Mn (6.6% of revenue). Chairman and Managing Director Glenn Saldanha said North America is expected to gain momentum from FY26 onwards, supported by the respiratory and injectable portfolio. Management also said MHRA authorization for WINLEVI was secured in the UK, and that the company continues to explore strategic partnerships for the ISB 2001 asset. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Feb 2025 | results Results | Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryGlenmark Pharmaceuticals filed unaudited standalone and consolidated financial results for the third quarter and nine months ended 31 December 2024, approved by the Board on 14 February 2025. Consolidated total income for Q3 FY25 (quarter ended 31 December 2024) was Rs 34,186.80 million, against Rs 25,521.12 million in the corresponding quarter of the prior year (Rs million). Consolidated profit before tax from continuing operations for Q3 FY25 was Rs 4,563.26 million; consolidated profit after tax attributable to owners was Rs 3,479.62 million for the quarter. Standalone total income for Q3 FY25 was Rs 22,512.80 million, and standalone profit after tax from continuing operations was Rs 4,138.03 million (figures in Rs million). The results were subjected to a limited review by statutory auditors, who issued an unmodified report. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Dec 2024 | acquisition Acquisition, Capex | Glenmark Pharmaceuticals Limited has informed the Exchange about AcquisitionAI summaryGlenmark Pharmaceuticals has acquired a 34% stake in O2 Renewable Energy XXIV Private Limited, a solar and renewable energy SPV, under the securities subscription and shareholders' agreement referred to in its May 10, 2024 intimation. Total investment is up to Rs. 1.99 crore in equity and compulsorily convertible debentures; Rs. 1.75 crore has been invested so far, comprising Rs. 17 lakhs for 34% of equity and Rs. 158 lakhs in CCDs (34.57%). The consideration is cash; the target was incorporated on February 20, 2024 and has no turnover yet. The acquisition is not a related party transaction, and no promoter or group company has an interest in the entity. The SPV becomes an associate of Glenmark, supporting its carbon-neutral-by-2030 target and captive renewable power compliance; no governmental or regulatory approvals are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Nov 2024 | transcript | Glenmark Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryGlenmark Pharmaceuticals filed a letter with the exchanges (NSE and BSE) on 21 November 2024 stating that the transcript of its Q2 FY2025 earnings call, held on 18 November 2024 for the quarter ended 30 September 2024, has been uploaded to the company website. The filing is a notice of the transcript's publication under SEBI LODR Regulation 30(6); the transcript itself is not included in the pages provided. The letter was signed by Harish Kuber, Company Secretary & Compliance Officer. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.